CURARAD Trademark

Trademark Overview


On Thursday, March 15, 2018, a trademark application was filed for CURARAD with the United States Patent and Trademark Office. The USPTO has given the CURARAD trademark a serial number of 87836342. The federal status of this trademark filing is CANCELLED - SECTION 8 as of Friday, November 14, 2025. This trademark is owned by CuraCloud Corporation. The CURARAD trademark is filed in the Computer & Software Services & Scientific Services category with the following description:

Providing software as a service (SaaS) services featuring software for use in medical diagnostics, medical image analysis, medical screening, medical testing, DNA screening for medical purposes, and genetic testing for medical purposes; providing software as a service (SaaS) services featuring software for the analysis of medical data, namely, medical imaging data, health care data, health records, medical records, and genomic data for use in the prevention, diagnosis and treatment of medical conditions, analyzing clinical trials, analyzing drug interactions, development of vaccines and medicines, analyzing medical diagnostic data, analyzing molecular medicine data, analyzing precision medicine data, and structural and functional analysis of genomes; providing software as a service (SaaS) services featuring software for the analysis of genomic data for use in tracking variation and mutation of pathogens; providing software as a service (SaaS) services featuring software for determining...
curarad

General Information


Serial Number87836342
Word MarkCURARAD
Filing DateThursday, March 15, 2018
Status710 - CANCELLED - SECTION 8
Status DateFriday, November 14, 2025
Registration Number5741258
Registration DateTuesday, April 30, 2019
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, August 21, 2018

Trademark Statements


Goods and ServicesProviding software as a service (SaaS) services featuring software for use in medical diagnostics, medical image analysis, medical screening, medical testing, DNA screening for medical purposes, and genetic testing for medical purposes; providing software as a service (SaaS) services featuring software for the analysis of medical data, namely, medical imaging data, health care data, health records, medical records, and genomic data for use in the prevention, diagnosis and treatment of medical conditions, analyzing clinical trials, analyzing drug interactions, development of vaccines and medicines, analyzing medical diagnostic data, analyzing molecular medicine data, analyzing precision medicine data, and structural and functional analysis of genomes; providing software as a service (SaaS) services featuring software for the analysis of genomic data for use in tracking variation and mutation of pathogens; providing software as a service (SaaS) services featuring software for determining and predicting patterns in data, namely, medical data, genomic data, proteomic data, metabolomics data, transcriptomic data, nutritional and nutrigenomics data, medical imaging data, health care data, health records, medical records, genomic data, and environmental factor data; providing software as a service (SaaS) services featuring software for executing preconfigured non-field specific machine learning and deep learning algorithms and processes for the purposes of uploading and managing data for the training of preconfigured data models implemented on a hosted software platform utilizing said machine learning and deep learning processes and for utilizing said trained data models for use in medical diagnostics, medical image analysis, medical screening, medical testing, DNA screening for medical purposes, and genetic testing for medical purposes; providing software as a service (SaaS) services featuring software for conducting natural language processing on medical records to transform unstructured data into structured data supporting clinical and research use; research, development, testing, and deployment of immunotherapy drugs all being pharmaceutical drug development services; Platform as a service (PaaS) featuring computer software platforms for providing clinical decision support for patient care; providing scientific analysis in the field of next generation sequencing (NGS), namely, the analysis and interpretation of genomic data

Classification Information


International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code2 - Sec. 8 - Entire Registration
Class Status DateFriday, November 14, 2025
Primary Code042
First Use Anywhere DateMonday, December 31, 2018
First Use In Commerce DateMonday, December 31, 2018

Trademark Owner History


Party NameKEYAMED NA INC.
Party Type31 - New Owner After Registration
Legal Entity Type03 - Corporation
AddressSEATTLE, WA 98104

Party NameCuraCloud Corporation
Party Type30 - Original Registrant
Legal Entity Type03 - Corporation
AddressSeattle, WA 98104

Party NameCuraCloud Corporation
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressSeattle, WA 98104

Party NameCuraCloud Corporation
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressSeattle, WA 98104

Trademark Events


Event DateEvent Description
Monday, March 19, 2018NEW APPLICATION ENTERED
Thursday, March 22, 2018NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Tuesday, June 26, 2018ASSIGNED TO EXAMINER
Monday, July 2, 2018EXAMINERS AMENDMENT -WRITTEN
Monday, July 2, 2018EXAMINERS AMENDMENT E-MAILED
Monday, July 2, 2018NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Monday, July 2, 2018EXAMINER'S AMENDMENT ENTERED
Monday, July 2, 2018APPROVED FOR PUB - PRINCIPAL REGISTER
Monday, July 16, 2018ASSIGNED TO LIE
Wednesday, August 1, 2018NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, August 21, 2018PUBLISHED FOR OPPOSITION
Tuesday, August 21, 2018OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, October 16, 2018NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Thursday, February 28, 2019TEAS STATEMENT OF USE RECEIVED
Wednesday, March 20, 2019CASE ASSIGNED TO INTENT TO USE PARALEGAL
Thursday, February 28, 2019USE AMENDMENT FILED
Friday, March 22, 2019STATEMENT OF USE PROCESSING COMPLETE
Wednesday, March 27, 2019ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
Thursday, March 28, 2019NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
Tuesday, April 30, 2019REGISTERED-PRINCIPAL REGISTER
Wednesday, February 24, 2021AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
Tuesday, April 30, 2024COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
Wednesday, April 16, 2025TEAS CHANGE OF OWNER ADDRESS RECEIVED
Wednesday, April 16, 2025APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Wednesday, April 16, 2025TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Wednesday, April 16, 2025ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Wednesday, April 16, 2025TEAS CHANGE OF CORRESPONDENCE RECEIVED
Monday, May 12, 2025TEAS WITHDRAWAL OF ATTORNEY RECEIVED
Monday, May 12, 2025WITHDRAWAL OF ATTORNEY GRANTED
Friday, November 14, 2025CANCELLED SEC. 8 (6-YR)